S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
NASDAQ:ECYT

Endocyte Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$23.99
0.00 (0.00 %)
(As of 12/21/2018)
Add
Compare
Today's Range
$23.99
$23.99
50-Day Range N/A
52-Week Range
$2.81
$24.00
VolumeN/A
Average Volume2.12 million shs
Market Capitalization$1.97 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.01

Receive ECYT News and Ratings via Email

Sign-up to receive the latest news and ratings for Endocyte and its competitors with MarketBeat's FREE daily newsletter.


Endocyte logo

About Endocyte

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:ECYT
CUSIP
29269A10
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$70,000.00
Price / Sales
28,133.42
Book Value
$1.99 per share

Profitability

Net Income
$-55.06 million
Net Margins
-32,296.09%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$1.97 billion
Next Earnings Date
N/A
Optionable
Optionable

MarketRank

Overall MarketRank

1.43 out of 5 stars

Medical Sector

1072nd out of 1,358 stocks

Pharmaceutical Preparations Industry

517th out of 666 stocks

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












Endocyte (NASDAQ:ECYT) Frequently Asked Questions

What stocks does MarketBeat like better than Endocyte?

Wall Street analysts have given Endocyte a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Endocyte wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Endocyte's earnings last quarter?

Endocyte, Inc. (NASDAQ:ECYT) issued its quarterly earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.01. The biopharmaceutical company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.02 million. Endocyte had a negative net margin of 32,296.09% and a negative trailing twelve-month return on equity of 21.19%.
View Endocyte's earnings history
.

Who are Endocyte's key executives?

Endocyte's management team includes the following people:
  • Mr. Michael A. Sherman, CEO, Pres & Director (Age 52)
  • Mr. Michael T. Andriole, Chief Financial Officer (Age 45)
  • Dr. Alison A. Armour, Chief Medical Officer (Age 54)
  • Dr. Christopher P. Leamon, VP of R&D (Age 52)
  • Dr. Philip S. Low, Co-Founder, Chief Science Officer & Director (Age 70)

What other stocks do shareholders of Endocyte own?

What is Endocyte's stock symbol?

Endocyte trades on the NASDAQ under the ticker symbol "ECYT."

What is Endocyte's stock price today?

One share of ECYT stock can currently be purchased for approximately $23.99.

How much money does Endocyte make?

Endocyte has a market capitalization of $1.97 billion and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-55.06 million in net income (profit) each year or ($1.00) on an earnings per share basis.

What is Endocyte's official website?

The official website for Endocyte is www.endocyte.com.

Where are Endocyte's headquarters?

How can I contact Endocyte?

Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company can be reached via phone at 765-463-7175.


This page was last updated on 10/23/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.